Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism
ConditionAutism
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age4-14
SponsorUniversity of Jordan
About this trial
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.
Eligibility criteria
Qualifiers
14 subjects, 4-14 years of age, will be enrolled into this study, who meet the criteria for (ASD
Disqualifiers
Age > 14 years.
Patient weighing < 10 kg.
History of severe Allergy
History of severe head trauma, defined by loss of consciousness or hospitalization, skull fracture, or stroke.
Trial design
Treatments tested in this trial
- WJMSC
Treatment groups
14 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov